Literature DB >> 11157502

Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency.

R J Rubocki1, J R Parsa, M S Hershfield, W G Sanger, S J Pirruccello, I Santisteban, B G Gordon, S E Strandjord, P I Warkentin, P F Coccia.   

Abstract

Bone marrow transplantation (BMT) for severe combined immunodeficiency (SCID) with human leukocyte antigen (HLA)-identical sibling donors but no pretransplantation cytoreduction results in T-lymphocyte engraftment and correction of immune dysfunction but not in full hematopoietic engraftment. A case of a 17-month-old girl with adenosine deaminase (ADA) deficiency SCID in whom full hematopoietic engraftment developed after BMT from her HLA-identical sister is reported. No myeloablative or immunosuppressive therapy or graft-versus-host disease (GVHD) prophylaxis was given. Mild acute and chronic GVHD developed, her B- and T-cell functions became reconstituted, and she is well almost 11 years after BMT. After BMT, repeated studies demonstrated: (1) Loss of a recipient-specific chromosomal marker in peripheral blood leukocytes (PBLs) and bone marrow, (2) conversion of recipient red blood cell antigens to donor type, (3) conversion of recipient T-cell, B-cell, and granulocyte lineages to donor origin by DNA analysis, and (4) increased ADA activity and metabolic correction in red blood cells and PBLs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157502     DOI: 10.1182/blood.v97.3.809

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

2.  Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency.

Authors:  Chimene Kesserwan; Robert Sokolic; Edward W Cowen; Elizabeth Garabedian; Kerstin Heselmeyer-Haddad; Chyi-Chia Richard Lee; Stefania Pittaluga; Clarymar Ortiz; Kristin Baird; Dolores Lopez-Terrada; Julia Bridge; Alan S Wayne; Fabio Candotti
Journal:  J Allergy Clin Immunol       Date:  2011-12-06       Impact factor: 10.793

3.  Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.

Authors:  Sachit A Patel; Don W Coulter; Alfred C Grovas; Bruce G Gordon; James L Harper; Phyllis I Warkentin; James L Wisecarver; Warren G Sanger; Peter F Coccia
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.